NitroMed to axe BiDil reps

Share this article:
NitroMed to axe BiDil reps
NitroMed to axe BiDil reps

NitroMed announced it plans to lay off a majority of its newly hired BiDil sales force by roughly 70 to 90 employees.
 
NitroMed doubled its sales force from 30 to 60 specialist reps during the second half of 2007 to boost BiDil prescriptions. BiDil is indicated for the treatment of heart failure in self-identified black patients.

“However, with only modest improvement in sales, management concluded that it cannot sustain BiDil marketing efforts alone,” wrote Friedman, Billings, Ramsey & Co. analyst Robert Uhl in a recent note to investors.

Nitromed now expects to file the NDA for BiDil XR, the once-daily extended release formulation, with the FDA in 2010.
 
Nitromed has also hired an investment bank to explore strategic options, which could lead to sale of the company, Uhl wrote.

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...